Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Total Valuation
Kura Oncology has a market cap or net worth of $472.55M. The enterprise value is $48.15M.
Market Cap$472.55M
Enterprise Value$48.15M
Share Statistics
Kura Oncology has 80.78M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding80.78M
Owned by Insiders1.47%
Owned by Instutions1.52%
Financial Efficiency
Kura Oncology’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -28.42%.
Return on Equity (ROE)-42.06%
Return on Assets (ROA)-22.89%
Return on Invested Capital (ROIC)-28.42%
Return on Capital Employed (ROCE)-28.35%
Revenue Per Employee$280,640.625
Profits Per Employee-$906,161.458
Employee Count192
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kura Oncology is -4.31. Kura Oncology’s PEG ratio is 1.50.
PE Ratio-4.31
PS Ratio13.93
PB Ratio1.81
Price to Fair Value1.81
Price to FCF5.61
Price to Operating Cash Flow5.59
PEG Ratio1.50
Income Statement
In the last 12 months, Kura Oncology had revenue of $53.88M and earned -$173.98M in profits. Earnings per share was -$2.03.
Revenue$53.88M
Gross Profit$53.45M
Operating Income-$170.74M
Pretax Income-$171.97M
Net Income-$173.98M
EBITDA-175.39M
Earnings Per Share (EPS)-2.03
Cash Flow
In the last 12 months, operating cash flow was $134.32M and capital expenditures -$472.00K, giving a free cash flow of $133.84M billion.
Operating Cash Flow$134.32M
Free Cash Flow$133.84M
Free Cash Flow per Share$1.66
Dividends & Yields
Kura Oncology pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield17.84%
Earnings Yield-23.18%
Stock Price Statistics
Beta1.42
52-Week Price Change-67.56%
50-Day Moving Average7.42
200-Day Moving Average13.93
Relative Strength Index (RSI)35.11
Average Volume (3m)1.25M
Important Dates
Kura Oncology upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Kura Oncology as a current ratio of 9.46, with Debt / Equity ratio of 0.04
Current Ratio9.46
Quick Ratio9.46
Debt to Market Cap0.02
Net Debt to EBITDA1.23
Interest Coverage Ratio-119.33
Taxes
In the past 12 months, Kura Oncology has paid $2.21M in taxes.
Income Tax$2.21M
Effective Tax Rate-1.17%
Enterprise Valuation
Kura Oncology EV to EBITDA ratio is -3.20, with an EV/FCF ratio of 4.05.
EV to Sales10.07
EV to EBITDA-3.20
EV to Free Cash Flow4.05
EV to Operating Cash Flow4.04
Balance Sheet
Kura Oncology has $727.39M in cash and marketable securities with $16.59M in debt, giving a net cash position of -$710.80M billion.
Cash & Marketable Securities$727.39M
Total Debt$16.59M
Net Cash-$710.80M
Net Cash Per Share-$8.80
Tangible Book Value Per Share$4.80
Margins
Gross margin is 100.00%, with operating margin of -358.55%, and net profit margin of -322.89%.
Gross Margin100.00%
Operating Margin-358.55%
Pretax Margin-319.15%
Net Profit Margin-322.89%
EBITDA Margin-314.57%
EBIT Margin-316.14%
Analyst Forecast
The average price target for Kura Oncology is $25.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.00
Price Target Upside314.59%
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast
EPS Growth Forecast2.90%